Literature DB >> 6580948

Phase II study of amsacrine gluconate in refractory leukemia.

G A Omura, E F Winton, W R Vogler, K S Zuckerman, A J Grillo-Lopez.   

Abstract

Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation. There were two complete and two partial remissions. This preparation has no apparent advantage when compared with amsacrine lactate.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6580948

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  3 in total

Review 1.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

Review 2.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

3.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.